RecruitingPhase 1Phase 2NCT05548452

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial


Sponsor

Virginia Commonwealth University

Enrollment

80 participants

Start Date

Nov 21, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • \>18 years of age
  • Advanced liver disease
  • Able to give written, informed consent
  • Alcohol as a cause of advanced liver disease
  • Continued sustained drinking
  • Having previously declined a referral to traditional AUD therapy services or having failed such treatments

Exclusion Criteria24

  • Lack of sustained drinking
  • Recent or current alcoholic hepatitis
  • Alcohol withdrawal symptoms
  • Clinically significant use of illicit drugs
  • Uncontrolled mood disorders or primary psychotic conditions
  • MELD score\>17
  • Unclear diagnosis of chronic liver disease
  • Current hepatic encephalopathy on lactulose and/or rifaximin
  • WBC count\<1000
  • Non-elective hospitalization within last month
  • on dialysis
  • known untreated, in-situ luminal GI cancers
  • chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease)
  • Dysphagia within 2 weeks
  • History of aspiration, gastroparesis, intestinal obstruction
  • Ongoing absorbable antibiotic use
  • Severe anaphylactic food allergy
  • allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil)
  • Adverse event attributable to prior IMT
  • ASA Class IV or V
  • Pregnant or nursing patients
  • acute illness or fever on the day of planned FMT
  • Immunosuppression
  • Other conditions which make patients are poor candidate for this study per investigator judgement

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntestinal Microbiota Transplant (IMT) Capsules

Capsules containing freeze-dried intestinal microbiota from healthy human donors

DRUGPlacebo Capsules

Capsules containing an inactive substance ("sugar pill")


Locations(2)

Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, United States

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05548452


Related Trials